Abstract: A turbine airfoil (10) includes a flow displacement element (26A-B, 26A?-B?) positioned in an interior portion (11) of an airfoil body (12) between a pair of adjacent partition walls (24) and comprising a radially extending elongated main body (28). The main body (28) is spaced from the pressure and suction side walls (16, 18) and further spaced from one or both of the adjacent partition walls (24), whereby a first near wall passage (72) is defined between the main body (28) and the pressure side wall (16), a second near wall passage (74) is defined between the main body (28) and the pressure side wall (18) and a central channel (76) is defined between the main body (28) and a respective one of the adjacent partition walls (24). The central channel (76) is connected to the near wall passages (72, 74) along a radial extent.

Abstract: A compound shown by the following general formula (1-1), AR1 and AR2 each independently represent an aromatic ring or an aromatic ring containing at least one nitrogen and/or sulfur atom, two AR1s, AR1 and AR2, or two AR2s are optionally bonded; AR3 represents a benzene, naphthalene, thiophene, pyridine, or diazine ring; A represents an organic group; B represents an anionic leaving group; Y represents a divalent organic group; “p” is 1 or 2; “q” is 1 or 2; “r” is 0 or 1; “s” is 2 to 4; when s=2, Z represents a single bond, divalent atom, or divalent organic group; and when s=3 or 4, Z represents a trivalent or quadrivalent atom or organic group. This compound cures to form an organic film, and also forms an organic under layer film.

Abstract: A compound includes two or more structures shown by the following general formula (1-1) in the molecule, “Ar” represents an aromatic ring or one that contains at least one nitrogen atom and/or sulfur atom optionally having a substituent, and two Ars are optionally bonded with each other to form a ring structure; the broken line represents a bond with Y; Y represents a divalent or trivalent organic group having 6 to 30 carbon atoms that contains an aromatic ring or a heteroaromatic ring optionally having a substituent, the bonds of which are located in a structure of the aromatic ring or the heteroaromatic ring; R represents a hydrogen atom or a monovalent group having 1 to 68 carbon atoms. This compound can be cured even in an inert gas not only in air atmosphere without forming byproducts, and can form an organic under layer film.

Abstract: The present invention provides pharmaceutical formulations including a non-anticoagulant, non-saccharide polymer that with at least one sulfate or sulfonate moiety. The pharmaceutical formulations of the invention are of use to improve blood clotting in a subject. Also provided are useful analytical methods utilizing these polymers to query the dynamics of blood clotting in vitro.

Abstract: The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.

Abstract: A turbine airfoil (10) includes a flow displacement element (26) occupying a space between a pair of adjacent partition walls (24) in an interior portion (11) of a generally hollow airfoil body (12). The flow displacement element (26) includes an elongated main body (28) extending lengthwise in a radial direction and a pair of connector ribs (32, 34) respectively connecting the main body (28) to pressure and suction sides (16, 18) of the airfoil (10). A pair of adjacent radial flow passes (43-44, 45-46) of symmetrically opposed flow cross-sections are defined on chordally opposite sides of the flow displacement element (26). The radial flow passes (43-44, 45-46) conduct cooling fluid in opposite radial directions and are connected in series via a chordal passage (50a, 50c) defined in the interior portion (11) between the flow displacement element (26) and a radial end face (52) of the airfoil body (12), to form a serpentine cooling path (60a, 60b).

Abstract: A turbine airfoil (10) includes an elongated hollow body (26) defining a radial cavity (T1, T2) positioned in an airfoil interior (11). A pair of radial flow passes (B,E/C,D) incorporating near-wall cooling (72, 74) channels are formed on opposite sides of the elongated hollow body (26), which are in serial flow relationship conducting a coolant in opposite radial directions, forming a serpentine cooling path (60a, 60b). A downstream radial flow pass (C, D) of the serpentine cooling path (60a, 60b) is fluidically connected to the radial cavity (T1, T2). Relatively heated coolant from the serpentine cooling path is directed into the radial cavity (T1, T2) to warm the elongated hollow body (26). The coolant is subsequently discharged via impingement openings (90) on the elongated hollow body (26) into first and second impingement volumes (102, 104) that respectively adjoin the pressure and suction side walls (16, 18).

Abstract: The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.

Abstract: An airfoil (10) includes at least one internal cooling channel (A-F) extending in the radial direction and adjoined on opposite sides by an airfoil pressure sidewall (16) and an airfoil suction sidewall (18). An internal surface (16a) of the airfoil pressure sidewall (16) and an internal surface (18a) of the airfoil suction sidewall (18) define heat transfer surfaces in relation to a coolant flowing through the internal cooling channel (A-F). A flow splitter feature (90) is located in a flow path of the coolant in the internal cooling channel (A-F) between the pressure and suction sidewalls (16, 18). The flow splitter feature (90) is effective to create a flow separation region downstream of the flow splitter feature (90), whereby coolant flow velocity is locally increased along the internal surfaces (16a, 18a) of the pressure and suction sidewalls (16, 18).

Abstract: A turbine airfoil (10) includes a flow blocking body (26) positioned an internal cavity (40). A first near-wall cooling channel (72) is defined between the flow blocking body (26) and an airfoil pressure sidewall (16). A second near-wall cooling channel (74) is defined between the flow blocking body (26) and an airfoil suction sidewall (18). A connecting channel (76) is defined between the flow blocking body (26) an internal partition wall (24) that connects the airfoil pressure (16) and suction (18) sidewalls. The connecting channel (76) is connected to the first (72) and second (74) near-wall cooling channels along a radial extent. Turbulating features (90, 90a-b) are located in the connecting channel (76) and are formed on the flow blocking body (26) and/or on the partition wall (24). The turbulating features (90, 90a-b) are effective to produce a higher coolant flow rate through the first (72) and second (74) near-wall cooling channels in comparison to the connecting channel (76).

Abstract: Polymeric compositions, methods, and delivery devices for inhibiting bleeding are disclosed. The method includes applying a dried material topically to a wound site, where the material may include a cross-linked biologically compatible polymer which forms a hydrogel when exposed to blood and where the material may not include an active agent such as thrombin. A spring-loaded delivery device as described herein may be used to apply the dried material.

Abstract: A turbine airfoil (10) includes a flow displacement element (26A-B, 26A?-B?) positioned in an interior portion (11) of an airfoil body (12) between a pair of adjacent partition walls (24) and comprising a radially extending elongated main body (28). The main body (28) is spaced from the pressure and suction side walls (16, 18) and further spaced from one or both of the adjacent partition walls (24), whereby a first near wall passage (72) is defined between the main body (28) and the pressure side wall (16), a second near wall passage (74) is defined between the main body (28) and the pressure side wall (18) and a central channel (76) is defined between the main body (28) and a respective one of the adjacent partition walls (24). The central channel (76) is connected to the near wall passages (72, 74) along a radial extent.

Abstract: A single-handed applicator system includes an applicator, including a body and a bore defined by the body. The bore has a first end and a second end. The applicator includes a trigger, coupled to the body. The applicator includes a gear system, disposed within the body. The gear system engages with both a portion of a removable stylus and the trigger to actuate the trigger and rotate a gear along at least the portion of the removable stylus. The applicator system includes a delivery tube, configured to engage with the applicator at the first end of the bore. The applicator includes the removable stylus, configured to be received by the applicator at the second end of the bore. The removable stylus is configured to extend through both the bore and at least a portion of the delivery tube.

Abstract: The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.

Abstract: A turbine airfoil (10) includes a flow displacement element (26) occupying a space between a pair of adjacent partition walls (24) in an interior portion (11) of a generally hollow airfoil body (12). The flow displacement element (26) includes an elongated main body (28) extending lengthwise in a radial direction and a pair of connector ribs (32, 34) respectively connecting the main body (28) to pressure and suction sides (16, 18) of the airfoil (10). A pair of adjacent radial flow passes (43-44, 45-46) of symmetrically opposed flow cross-sections are defined on chordally opposite sides of the flow displacement element (26). The radial flow passes (43-44, 45-46) conduct cooling fluid in opposite radial directions and are connected in series via a chordal passage (50a, 50c) defined in the interior portion (11) between the flow displacement element (26) and a radial end face (52) of the airfoil body (12), to form a serpentine cooling path (60a, 60b).

Abstract: A turbine airfoil (10) includes an impingement structure (26A, 26B) comprising a hollow elongated main body (28) positioned in an interior portion (11) of an airfoil body (12). The main body (28) extends lengthwise along a radial direction and defines coolant cavity (64) therewithin that receives a cooling fluid (60). The main body (28) is spaced from a pressure side wall (16) and a suction side wall (18) of the airfoil body (12) and may be spaced from an airfoil tip (52), to define respective passages (72, 74, 77) therebetween. A plurality of impingement openings (25) are formed through the main body (28) that connect the coolant cavity (64) with one or more of the respective passages (72, 74, 77). The impingement openings (25) direct the cooling fluid (60) flowing in the coolant cavity (64) to impinge on the pressure and/or suction side walls (16, 18) and/or the airfoil tip (52).

Abstract: A railway inspection system for monitoring defects of a rail, including an inspection vehicle configured for traversing the rail, a sensor disposed on the vehicle configured for obtaining rail condition data, a memory disposed on the vehicle and storing previous rail condition data from a previous traversal of the rail, a display device disposed on the vehicle, a processor disposed on the vehicle and a non-transitory computer-readable medium disposed on the vehicle and containing instructions, which when executed by the processor, cause performance of the following steps in real-time as the vehicle traverses the rail, namely obtaining current rail condition data from the sensor, displaying on the display device representative images of the current rail condition data, retrieving the previous rail condition data from the memory, and displaying on the display device representative images of the previous rail condition data.

Abstract: Fabrics that have been treated to create superhydrophobic, oleophobic and/or ice-phobic performance are manufactured or assembled in specific conforming shapes so they can be positioned on or pulled over and around certain objects for the purpose of making those objects superhydrophobic, oleophobic and/or ice-phobic so they are self-cleaning, water proof, ice-resistant, oil-resistant, corrosion barriers, etc.

Abstract: The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.

Abstract: A method for immobilizing dyes and antimicrobial agents on a polymeric cover or housing for a medical device is disclosed and described. The surface may be that of a catheter, a connector, a drug vial spike, a bag spike, a prosthetic device, an endoscope, a surface of an infusion pump, a key pad, a touch screen or a handle. The surfaces may also be one or more of those associated with a infusion of a medicament or dialysis treatment, such as peritoneal dialysis or hemodialysis, where it is important that the working surface for the dialysis fluid be sterile. These surfaces include connectors for peritoneal dialysis sets or for hemodialysis sets, bag spikes, dialysis catheters, and so forth. A method for determining whether a surface has been sterilized, and a dye useful in so indicating, is also disclosed.